Stockscreener 앱 받기
2.08
4.59%
-0.10
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
DekaBank Deutsche Girozentrale Sells 115,287 Shares of GT Biopharma, Inc. (NASDAQ:GTBP) - Defense World
GT Biopharma announces officer role change By Investing.com - Investing.com Australia
GT Biopharma announces officer role change By Investing.com - Investing.com Canada
GT Biopharma announces officer role change - Investing.com
GT Biopharma announces officer role change By Investing.com - Investing.com UK
Systemic Mastocytosis Market to Witness Growth by 2032 | AB - openPR
Nanobodies Market Set to Witness | Significant Growth by 2024-2031 | Proteintech Group, Inc., GT Biopharma, - EIN News
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
NK Cell Therapy Treatment Drugs, Clinical Trials, Emerging Therapies and Companies 2024 - openPR
GTBP stock touches 52-week low at $2.06 amid market challenges - Investing.com Australia
GTBP stock touches 52-week low at $2.06 amid market challenges - Investing.com
GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update - Defense World
GT Biopharma : Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference - Marketscreener.com
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024 - MSN
Exponential Growth Expected for Nanobodies Market Expected to Expand at a Steady 2024-2031 - WhaTech
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024 - InvestorPlace
GTBP stock touches 52-week low at $2.2 amid market challenges - Investing.com India
GTBP stock touches 52-week low at $2.2 amid market challenges - Investing.com
GTBP stock touches 52-week low at $2.2 amid market challenges - Investing.com Canada
GTBP stock touches 52-week low at $2.2 amid market challenges - Investing.com UK
Nanobodies Market Current Evaluation and Long-Term Growth - openPR
GTBP stock touches 52-week low at $2.52 amid market challenges - Investing.com
GTBP stock touches 52-week low at $2.52 amid market challenges - Investing.com India
Anthony Cataldo Is Assembling The Team To Fight Cancer - Yahoo Canada Shine On
Cracking The Code: Understanding Analyst Reviews For Doximity - Quantisnow
Second-Generation NK Cell Engager Heading to Trial for CD33+ Leukemia - CGTLive™
NK Cell Therapy Pipeline 2024 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Sc - Barchart
NK Cell Therapy Pipeline 2024 | ImmunityBio, Cantargia, - openPR
Rithem Life Sciences Announces Formation of Board of Directors - Quantisnow
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference - Quantisnow
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer - Quantisnow
GT Biopharma Inc (GTBP) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
FDA grants IND clearance for GT Biopharma’s Phase I leukaemia treatment trial - Yahoo Finance
AFG appoints new Vice President & Chief Information Security Officer By Investing.com - Investing.com India
RBC maintains BlackBerry sector perform rating, $3 stock price target By Investing.com - Investing.com Canada
GT Biopharma gains FDA nod for cancer trial By Investing.com - Investing.com Australia
Diamond Hill CEO buys shares worth over $76k By Investing.com - Investing.com
Xylo affiliate secures first commercial wireless EV charging order By Investing.com - Investing.com
Fortrea launches AI studio to enhance clinical trials By Investing.com - Investing.com
SoundHound AI announces mandatory conversion of Series A Preferred Stock By Investing.com - Investing.com
GT Biopharma gains FDA nod for cancer trial By Investing.com - Investing.com UK
Saba capital management buys $1.4k of abrdn Life Sciences stock By Investing.com - Investing.com South Africa
Sunrise New Energy secures $13.76 million loan from CCB By Investing.com - Investing.com India
GT Biopharma gains FDA nod for cancer trial By Investing.com - Investing.com India
Zuanic and Associates starts Tilray coverage with Neutral rating By Investing.com - Investing.com India
Understanding GTBP's financial ratios: A beginner's guide – US Post News - US Post News
GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study - Morningstar
GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study - MarketWatch
GT Biopharma Announces FDA Clearance of Investigational New - GlobeNewswire
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell ... - Quantisnow
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy - Yahoo Sport Australia
AbbVie, Merck Rack Up Approvals in UC, Endometrial Cancer and Pneumonia - BioSpace
Nanobodies Market Forecast for 2024-2031: Size, Trends, Shares, Insights |Merck KGaA, Sanofi, AlpalifeB Inc, GenScript - openPR
1.07%
5.70%
자본화:
|
볼륨(24시간):